John Hill

John Hill is the current Senior Vice President at Biosplice Therapeutics, overseeing the company's Chemistry group, Tumor Biology group, and CMC activities. Prior to Biosplice, John held various leadership roles at Pfizer, including Vice President and Head of Early Development Asset Team Leadership Group. John also worked at Pharmacyclics, Amgen, Miravant Medical Technologies, and The Royal Melbourne Hospital, where John led research and development efforts in oncology and neuro-oncology. John holds a Ph.D. from the University of Melbourne, along with other degrees in educational psychology and genetics.